The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development

Proteomics - Clinical Applications

Volumn 9, Issue 7-8, 2015, Pages 732-744

  Heikkinen, Aki T ^a,c   Lignet, Floriane ^b   Cutler, Paul ^b   Parrott, Neil ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Admescope Ltd   (Finland)

Author keywords

Absolute quantification; In vitro to in vivo extrapolation; Pharmacoproteomics; SRM; Targeted proteomics

Indexed keywords

CYTOCHROME P450 2B; CYTOCHROME P450 2B11; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A12; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; PROTEOME;

ACTIVE TRANSPORT; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GENE EXPRESSION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; HUMAN; MOLECULAR MODEL; NONHUMAN; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RNA DEGRADATION; RNA SYNTHESIS; ABSORPTION; ANIMAL; BIOLOGICAL MODEL; METABOLISM; MOLECULAR LIBRARY; PROCEDURES;

ABSORPTION, PHYSIOLOGICAL; ANIMALS; DRUG DISCOVERY; HUMANS; METABOLISM; MODELS, BIOLOGICAL; PROTEOME; PROTEOMICS; SMALL MOLECULE LIBRARIES;

EID: 84949110726     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400147     Document Type: Review

References (130)

1. Drug Metabolism in Drug Design and Development: Basic Concepts and Practice, John Wiley & Sons, Inc, Hoboken, NJ 2008.
2. Parkinson, A., Ogilvie, B. W., Buckley, D. B., Kazmi, F. et al., in: Klaassen, C. (Ed.), Casarett & Doull's Toxicology, The Basic Science of Poisons, McGraw-Hill Education, New York 2013, pp. 185-366.
3. Keogh, J. P., Gabrielle, M. H., Advances in Pharmacology, Academic Press 2012, pp. 1-42.
4. Jones, H., Rowland-Yeo, K., Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2013, 2, e63.
5. Mumtaz, M., Fisher, J., Blount, B., Ruiz, P., Application of physiologically based pharmacokinetic models in chemical risk assessment. J. Toxicol. 2012, 2012, 904603.
6. Reddy, M., Yang, R. S. H., Andersen, M. E., Clevell, H. J., Physiologically Based Pharmacokinetic Modeling: Science and Applications, Wiley, New York 2005.
7. Houston, J. B., Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 1994, 47, 1469-1479.
8. Rodgers, T., Leahy, D., Rowland, M., Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94, 1259-1276.
9. Rodgers, T., Rowland, M., Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006, 95, 1238-1257.
10. Berezhkovskiy, L. M., Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J. Pharm. Sci. 2004, 93, 364-374.
11. Poulin, P., Theil, F. P., Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 2002, 91, 129-156.
12. Rowland, M., Peck, C., Tucker, G., Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 45-73.
13. Parrott, N., Lave, T., Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 2008, 5, 760-775.
14. Houston, J. B., Galetin, A., Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab. 2008, 9, 940-951.
15. Miners, J. O., Mackenzie, P. I., Knights, K. M., The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzymeselective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab. Rev. 2010, 42, 189-201.
16. Jamei, M., Bajot, F., Neuhoff, S., Barter, Z. et al., A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin. Pharmacokinet. 2014, 53, 73-87.
17. Jones, H. M., Barton, H. A., Lai, Y., Bi, Y. A. et al., Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 2012, 40, 1007-1017.
18. Zamek-Gliszczynski, M. J., Lee, C. A., Poirier, A., Bentz, J. et al., ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin. Pharmacol. Ther. 2013, 94, 64-79.
19. Bosgra, S., vande Steeg, E., Vlaming, M. L., Verhoeckx, K. C. et al., Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. Eur. J. Pharm. Sci. 2014, 65, 156-166.
20. Neuhoff, S., Yeo, K. R., Barter, Z., Jamei, M. et al., Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J. Pharm. Sci. 2013, 102, 3161-3173.
21. Neuhoff, S., Yeo, K. R., Barter, Z., Jamei, M. et al., Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J. Pharm. Sci. 2013, 102, 3145-3160.
22. Varma, M. V., Lai, Y., Feng, B., Litchfield, J. et al., Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm. Res. 2012, 29, 2860-2873.
23. Vildhede, A., Karlgren, M., Svedberg, E. K., Wisniewski, J. R. et al., Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab. Dispos. 2014, 42, 1210-1218.
24. Johnson, T. N., Rostami-Hodjegan, A., Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth. 2011, 21, 291-301.
25. Edginton, A. N., Willmann, S., Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 2008, 47, 743-752.
26. Huang, S. M., Rowland, M., The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther. 2012, 91, 542-549.
27. Zhao, P., Rowland, M., Huang, S. M., Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 2012, 92, 17-20.
28. Manolis, E., Pons, G., Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br. J. Clin. Pharmacol. 2009, 68, 493-501.
29. Huang, S. M., Abernethy, D. R., Wang, Y., Zhao, P., Zineh, I., The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 2013, 102, 2912-2923.
30. Leong, R., Vieira, M. L., Zhao, P., Mulugeta, Y. et al., Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther 2012, 91, 926-931.
31. Rostami-Hodjegan, A., Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 2012, 92, 50-61.
32. Heikkinen, A. T., Fowler, S., Gray, L., Li, J. et al., In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver. Mol. Pharm. 2013, 10, 1388-1399.
33. Huang, S. M., Rowland, M., The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther. 2012, 91, 542-549.
34. Barter, Z. E., Tucker, G. T., Rowland-Yeo, K., Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 2013, 52, 1085-1100.
35. Johnson, T. N., Boussery, K., Rowland-Yeo, K., Tucker, G. T., Rostami-Hodjegan, A., A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 2010, 49, 189-206.
36. Johnson, T. N., Rostami-Hodjegan, A., Tucker, G. T., Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 2006, 45, 931-956.
37. Plowchalk, D. R., Rowland Yeo, K., Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur. J. Clin. Pharmacol. 2012, 68, 951-960.
38. Troberg, J., Jarvinen, E., Muniz, M., Sneitz, N. et al., Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity. Drug Metab. Dispos. 2015, 43, 107-118.
39. Martignoni, M., Groothuis, G. M., deKanter, R., Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006, 2, 875-894.
40. Xia, C. Q., Xiao, G., Liu, N., Pimprale, S. et al., Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays. Mol. Pharm. 2006, 3, 78-86.
41. Jones, H. M., Parrott, N., Jorga, K., Lave, T., A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 2006, 45, 511-542.
42. Uchida, Y., Wakayama, K., Ohtsuki, S., Chiba, M. et al., Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 2014, 350, 578-588.
43. Uchida, Y., Ohtsuki, S., Kamiie, J., Terasaki, T., Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J. Pharmacol. Exp. Ther. 2011, 339, 579-588.
44. Meyer, M., Schneckener, S., Ludewig, B., Kuepfer, L., Lippert, J., Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab. Dispos. 2012, 40, 892-901.
45. Bolger, M. B., Lukacova, V., Woltosz, W. S., Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J. 2009, 11, 353-363.
46. Vogel, C., Marcotte, E. M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13, 227-232.
47. Watanabe, M., Kumai, T., Matsumoto, N., Tanaka, M. et al., Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J. Pharmacol. Sci. 2004, 94, 459-462.
48. Ohtsuki, S., Schaefer, O., Kawakami, H., Inoue, T. et al., Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 2012, 40, 83-92.
49. Harwood, M. D., Neuhoff, S., Carlson, G. L., Warhurst, G., Rostami-Hodjegan, A., Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm. Drug Dispos. 2013, 34, 2-28.
50. Qiu, X., Zhang, H., Lai, Y., Quantitative targeted proteomics for membrane transporter proteins: method and application. AAPS J. 2014, 16, 714-726.
51. Hersman, E. M., Bumpus, N. N., A targeted proteomics approach for profiling murine cytochrome P450 expression. J. Pharmacol. Exp. Ther. 2014, 349, 221-228.
52. Oswald, S., Groer, C., Drozdzik, M., Siegmund, W., Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters. AAPS J. 2013, 15, 1128-1140.
53. Bi, Y. A., Qiu, X., Rotter, C. J., Kimoto, E. et al., Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm. Drug Dispos. 2013, 34, 452-461.
54. Prasad, B., Unadkat, J. D., Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics. AAPS J. 2014, 16, 634-648.
55. Boja, E. S., Rodriguez, H., Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 2012, 12, 1093-1110.
56. Calvo, E., Camafeita, E., Fernandez-Gutierrez, B., Lopez, J. A., Applying selected reaction monitoring to targeted proteomics. Expert Rev. Proteomics 2011, 8, 165-173.
57. Elschenbroich, S., Kislinger, T., Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery. Mol. Biosyst. 2011, 7, 292-303.
58. Elliott, M. H., Smith, D. S., Parker, C. E., Borchers, C., Current trends in quantitative proteomics. J. Mass Spectrom. 2009, 44, 1637-1660.
59. Ohtsuki, S., Hirayama, M., Ito, S., Uchida, Y. et al., Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics. Expert Rev. Proteomics 2014, 11, 303-313.
60. Ohtsuki, S., Uchida, Y., Kubo, Y., Terasaki, T., Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J. Pharm. Sci. 2011, 100, 3547-3559.
61. Uchida, Y., Tachikawa, M., Obuchi, W., Hoshi, Y. et al., A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 2013, 10, 21.
62. Janecki, D. J., Bemis, K. G., Tegeler, T. J., Sanghani, P. C. et al., A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme. Anal. Biochem. 2007, 369, 18-26.
63. Meech, R., Miners, J. O., Lewis, B. C., Mackenzie, P. I., The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacol. Ther. 2012, 134, 200-218.
64. Heikkinen, A. T., Friedlein, A., Matondo, M., Hatley, O. J. et al., Quantitative ADME proteomics - CYP and UGT enzymes in the beagle dog liver and intestine. Pharm. Res. 2015, 32, 74-90.
65. Harbourt, D. E., Fallon, J. K., Ito, S., Baba, T. et al., Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal. Chem. 2012, 84, 98-105.
66. Fujimoto, G. M., Monroe, M. E., Rodriguez, L., Wu, C. et al., Accounting for population variation in targeted proteomics. J. Proteome Res. 2014, 13, 321-323.
67. Barter, Z. E., Chowdry, J. E., Harlow, J. R., Snawder, J. E. et al., Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos. 2008, 36, 2405-2409.
68. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D. et al., Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 1997, 283, 1552-1562.
69. Barter, Z. E., Bayliss, M. K., Beaune, P. H., Boobis, A. R. et al., Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8, 33-45.
70. Harwood, M. D., Russell, M. R., Neuhoff, S., Warhurst, G., Rostami-Hodjegan, A., Lost in centrifugation: accounting for transporter protein losses in quantitative targeted absolute proteomics. Drug Metab. Dispos. 2014, 42, 1766-1772.
71. Achour, B., Russell, M. R., Barber, J., Rostami-Hodjegan, A., Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab. Dispos. 2014, 42, 500-510.
72. Deo, A. K., Prasad, B., Balogh, L., Lai, Y., Unadkat, J. D., Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab. Dispos. 2012, 40, 852-855.
73. Prasad, B., Evers, R., Gupta, A., Hop, C. E. et al., Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab. Dispos. 2014, 42, 78-88.
74. Prasad, B., Lai, Y., Lin, Y., Unadkat, J. D., Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J. Pharm. Sci. 2013, 102, 787-793.
75. Cubitt, H. E., Yeo, K. R., Howgate, E. M., Rostami-Hodjegan, A., Barter, Z. E., Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 2011, 41, 623-638.
76. Jahre, J. A., Grace, W. J., Greenbaum, D. M., Sarg, M. J., Jr., Medical approach to the hypotensive patient and the patient in shock. Heart Lung 1975, 4, 577-587.
77. Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C. et al., Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell. Proteomics 2014, 13, 907-917.
78. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
79. Balogh, L. M., Kimoto, E., Chupka, J., Zhang, H., Lai, Y., Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family. J. Proteomics Bioinform. 2013, 06, 229-236.
80. Prasad, B., Unadkat, J. D., Comparison of heavy labeled (SIL) peptide versus SILAC protein internal standards for LC-MS/MS quantification of hepatic drug transporters. Int. J. Proteomics 2014, 2014, 451-510.
81. Hanke, S., Besir, H., Oesterhelt, D., Mann, M., Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J. Proteome Res. 2008, 7, 1118-1130.
82. Russell, M. R., Achour, B., McKenzie, E. A., Lopez, R. et al., Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J. Proteome Res. 2013, 12, 5934-5942.
83. Shuford, C. M., Sederoff, R. R., Chiang, V. L., Muddiman, D. C., Peptide production and decay rates affect the quantitative accuracy of protein cleavage isotope dilution mass spectrometry (PC-IDMS). Mol. Cell. Proteomics 2012, 11, 814-823.
84. Meech, R., Mackenzie, P. I., Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol. 1997, 24, 907-915.
85. Sakaguchi, M., Mihara, K., Sato, R., A short amino-terminal segment of microsomal cytochrome P-450 functions both as an insertion signal and as a stop-transfer sequence. EMBO J. 1987, 6, 2425-2431.
86. Black, S. D., Membrane topology of the mammalian P450 cytochromes. FASEB J. 1992, 6, 680-685.
87. Achour, B., Barber, J., Rostami-Hodjegan, A., Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]. Drug Metab. Dispos. 2011, 39, 2130-2134.
88. Barr, J. T., Jones, J. P., Joswig-Jones, C. A., Rock, D. A., Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry. Mol. Pharm. 2013, 10, 3842-3849.
89. Kawakami, H., Ohtsuki, S., Kamiie, J., Suzuki, T. et al., Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J. Pharm. Sci. 2011, 100, 341-352.
90. Li, N., Nemirovskiy, O. V., Zhang, Y., Yuan, H. et al., Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal. Biochem. 2008, 380, 211-222.
91. Li, N., Palandra, J., Nemirovskiy, O. V., Lai, Y., LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal. Chem. 2009, 81, 2251-2259.
92. Li, N., Zhang, Y., Hua, F., Lai, Y., Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab. Dispos. 2009, 37, 66-73.
93. Qiu, X., Bi, Y. A., Balogh, L. M., Lai, Y., Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. J. Pharm. Sci. 2013, 102, 3252-3263.
94. Li, N., Singh, P., Mandrell, K. M., Lai, Y., Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol. Pharm. 2010, 7, 630-641.
95. Sato, Y., Nagata, M., Tetsuka, K., Tamura, K. et al., Optimized methods for targeted peptide-based quantification of human uridine 5'-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 2014, 42, 885-889.
96. Ji, C., Tschantz, W. R., Pfeifer, N. D., Ullah, M., Sadagopan, N., Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. Anal. Chim. Acta 2012, 717, 67-76.
97. Groer, C., Busch, D., Patrzyk, M., Beyer, K. et al., Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics. J. Pharm. Biomed. Anal. 2014, 100, 393-401.
98. Groer, C., Bruck, S., Lai, Y., Paulick, A. et al., LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. J. Pharm. Biomed. Anal. 2013, 85, 253-261.
99. Sakamoto, A., Matsumaru, T., Yamamura, N., Uchida, Y. et al., Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J. Pharm. Sci. 2013, 102, 3395-3406.
100. Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C. et al., Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 2011, 117, 333-345.
101. Heikkinen, A. T., Friedlein, A., Lamerz, J., Jakob, P. et al., Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog. Pharm. Res. 2012, 29, 1832-1842.
102. Hoshi, Y., Uchida, Y., Tachikawa, M., Inoue, T. et al., Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 2013, 102, 3343-3355.
103. Kamiie, J., Ohtsuki, S., Iwase, R., Ohmine, K. et al., Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 2008, 25, 1469-1483.
104. Ito, K., Uchida, Y., Ohtsuki, S., Aizawa, S. et al., Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J. Pharm. Sci. 2011, 100, 3939-3950.
105. Li, N., Bi, Y. A., Duignan, D. B., Lai, Y., Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol. Pharm. 2009, 6, 1180-1189.
106. Venkatakrishnan, K., vonMoltke, L. L., Court, M. H., Harmatz, J. S. et al., Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 2000, 28, 1493-1504.
107. Kamau, S. W., Kramer, S. D., Gunthert, M., Wunderli-Allenspach, H., Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. In Vitro Cell. Dev. Biol. 2005, 41, 207-216.
108. Proctor, N. J., Tucker, G. T., Rostami-Hodjegan, A., Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004, 34, 151-178.
109. Chen, Y., Liu, L., Nguyen, K., Fretland, A. J., Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab. Dispos. 2011, 39, 373-382.
110. Crewe, H. K., Barter, Z. E., Yeo, K. R., Rostami-Hodjegan, A., Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm. Drug Dispos. 2011, 32, 303-318.
111. Rostami-Hodjegan, A., Tucker, G. T., Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. 2007, 6, 140-148.
112. Baneyx, G., Parrott, N., Meille, C., Iliadis, A., Lave, T., Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. Eur. J. Pharm. Sci. 2014, 56, 1-15.
113. Fenneteau, F., Poulin, P., Nekka, F., Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J. Pharm. Sci. 2010, 99, 486-514.
114. Gertz, M., Harrison, A., Houston, J. B., Galetin, A., Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 2010, 38, 1147-1158.
115. Gertz, M., Houston, J. B., Galetin, A., Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos. 2011, 39, 1633-1642.
116. Heikkinen, A. T., Baneyx, G., Caruso, A., Parrott, N., Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates-an evaluation and case study using GastroPlus™. Eur. J. Pharm. Sci. 2012, 47, 375-386.
117. Yeo, K. R., Kenny, J. R., Rostami-Hodjegan, A., Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur. J. Clin. Pharmacol. 2013, 69, 1311-1320.
118. Zhou, S. F., Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 2009, 48, 689-723.
119. Vieira, M. D., Kim, M. J., Apparaju, S., Sinha, V. et al., PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin. Pharmacol. Ther. 2014, 95, 550-557.
120. Dickinson, G. L., Lennard, M. S., Tucker, G. T., Rostami-Hodjegan, A., The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br. J. Clin. Pharmacol. 2007, 64, 14-26.
121. Inoue, S., Howgate, E. M., Rowland-Yeo, K., Shimada, T. et al., Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 2006, 36, 499-513.
122. Achour, B., Rostami-Hodjegan, A., Barber, J., Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. Biopharm. Drug Dispos. 2014, 35, 353-361.
123. Fan, J., Chen, S., Chow, E. C., Pang, K. S., PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr. Drug Metab. 2010, 11, 743-761.
124. Karlgren, M., Vildhede, A., Norinder, U., Wisniewski, J. R. et al., Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J. Med. Chem. 2012, 55, 4740-4763.
125. Neuhoff, S., Tucker, G. T., Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions". Pharm. Res. 2013, 30, 1467-1468.
126. Varma, M. V., Lai, Y., Feng, B., Litchfield, J. et al., Response to the comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions". Pharm. Res. 2013, 30, 1469-1470.
127. Rowland Yeo, K., Aarabi, M., Jamei, M., Rostami-Hodjegan, A., Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev. Clin. Pharmacol. 2011, 4, 261-274.
128. Cheeti, S., Budha, N. R., Rajan, S., Dresser, M. J., Jin, J. Y., A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm. Drug Dispos. 2013, 34, 141-154.
129. Ghobadi, C., Johnson, T. N., Aarabi, M., Almond, L. M. et al., Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin. Pharmacokinet. 2011, 50, 809-822.
130. Huisinga, W., Solms, A., Fronton, L., Pilari, S., Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics Syst. Pharmacol. 2012, 1, e4.